The net proceeds from the issuance of 7,936,507 Equity Shares (worth Rs 800 crs) will be utilized to repay debt (Rs 600 crs), and the rest of the funds (Rs 200 crs) have been kept for general corporate purposes.

Emcure Pharma, established in 1981, is India's 13th-largest pharmaceutical company, engaged in developing, manufacturing, and globally marketing a diverse range of pharmaceutical products across 19 therapeutic areas. It caters to 70+ countries with a focus on India, Europe, and Canada. Region-wise revenue split (FY24): India - 48%, Europe - 21%, North America (predominantly Canada) - 14%, and Others (Emerging Markets) - 16%. Emcure holds a leadership position in gynecology and human immunodeficiency virus (HIV) (therapy areas in India in terms of Domestic Sales for MAT FY24).

• Leadership position in the gynecology segment, ranking as the no.1 player with a market share of 13.5% (in terms of Domestic Sales for MAT FY24). Provide brand offerings and medication across women's life cycles, which has aided in market share gains.
• Track record of building strong brands driven by the core pillars of innovation, R&D, quality focus, and patient-centric products. 6 of Emcure’s brands were ranked among the 300 highest-selling brands in IPM. 
• Established presence in the international markets (with Europe and Canada as focus markets) through inorganic expansion and diversified and fast-growing product portfolio of specialty branded generics, injectables, and generic products.
• Highly focused on the domestic business (48% of its revenues). Some of the growth levers include: i) Improve productivity of MRs, ii) Focus on expanding its presence in Tier 2 and 3 cities, iii) focus on R&D, iv) Evaluation of In-licensing deals and inorganic acquisitions, vi) Focus on Dermatology and CNS therapy areas where don't have a sufficient presence.

The following points should be kept in mind:

• Failure to adhere to quality standards stipulated by different regulators may affect the business's growth prospects.
• Higher products in the NLEM (National List of Essential Medicines) list, so any price implementation of Emcure’s leading products could affect profitability. As of FY24, 17% of domestic revenue was through NLEM products.
• A considerable portion of domestic revenue is derived from acute therapies (57%—FY24), which face high competitive intensity.